Latest news with #secukinumab
Medical News Today
4 days ago
- General
- Medical News Today
Cosentyx UnoReady and Sensoready pens: What to know about each
Cosentyx UnoReady (secukinumab) and Sensoready (secukinumab) are brand-name injections. They're both prescribed for plaque psoriasis, hidradenitis suppurativa, and certain types of arthritis. Certain factors may determine the injection pen that's right for you. This article explains the main similarities and differences between Cosentyx UnoReady and Sensoready. If you're considering taking one of these drugs, discussing this information with your doctor can help you decide if one of these treatments may be right for you. Cosentyx UnoReady and Sensoready have been approved by the Food and Drug Administration (FDA) to treat the following conditions in adults: Cosentyx UnoReady and Sensoready have been approved by the Food and Drug Administration (FDA) to treat the following conditions in children: The Cosentyx UnoReady pen and Sensoready pen are approved to treat the same conditions, but the pen you're prescribed may depend on your dosage. They also share some features, including: both pens come with a concealed needle, meaning you won't need to purchase needles or attach them to the pen. both pens will sound with a 'click' when the injection starts and when the injection is nearly finished, so you know that you receive the full dose. neither pen requires pressing a button to 'activate' the injection. both pens may be injected in the same body areas: your lower stomach, the front of your thighs, or your upper outer arms (if someone else is giving your injection). But there are differences between them that can determine whether one or the other is a better fit for you. Cosentyx is also available in prefilled syringes. If you'd like to learn about how Cosentyx UnoReady and Sensoready pens compare versus the prefilled syringe, ask your doctor or pharmacist. The Cosentyx UnoReady pen and Sensoready pen are approved to treat the same conditions, but the pen you're prescribed may depend on your dosage. The Cosentyx UnoReady pen delivers a 300-mg dose, while the Cosentyx Sensoready pen delivers a 150-mg dose. Two Sensoready pens may be used to deliver a 300-mg dose. Below are instructions for how to use the Cosentyx UnoReady pen. Your doctor or pharmacist will train you to use the pen to give yourself Cosentyx injections. Let them know if you have questions or concerns about how to use the UnoReady pen. Remove the Cosentyx UnoReady pen from the refrigerator 30 to 45 minutes before your dose. Doing so allows the pen to reach room temperature, making the injection more comfortable. Check the viewing window and ensure that the liquid is clear, and the color is colorless or slightly yellow. Air bubbles may also be visible, which is normal. Wash your hands, then clean the injection site with an alcohol wipe and allow it to dry. You may inject Cosentyx UnoReady doses into your lower stomach, the front of your thighs, or your upper outer arms (if someone else is giving your injection). Do not inject into skin that is bruised, hard, tender, scaly, or red or discolored. You also should not inject into an area of skin affected by psoriasis, or area with scars or stretch marks. Do not shake the UnoReady pen. shake the UnoReady pen. Remove and dispose of the cap. Position the UnoReady pen at a 90-degree angle against the injection site, with the viewing window facing you. Press the pen firmly against the skin and hold. You should hear the first 'click' sound, which indicates the injection has started. Keep holding the pen against your skin. Watch the viewing window on the UnoReady pen; you should see a moving green indicator, which shows the injection progress. You'll hear a second 'click' sound, which indicates the injection is nearly finished. After you hear the second 'click', hold the pen in place for another 5 seconds. Once the green indicator fills the viewing window and has stopped moving, you can remove the UnoReady pen from your skin and dispose of it in a sharps container. When you're first prescribed the Cosentyx Sensoready pen, your doctor or pharmacist will show you how to give yourself injections. Cosentyx Sensoready pen instructions are included below, but reach out to your doctor or pharmacist if you have questions or concerns about how to use Cosentyx Sensoready pens. Remove the Cosentyx Sensoready pen from the refrigerator 15 to 30 minutes before your dose. This allows the pen to reach room temperature, which helps make the injection more comfortable. Look at the Sensoready pen viewing window and ensure the liquid is clear with a colorless or slightly yellow appearance. Air bubbles may also appear, which is normal. If your prescribed dose is 150 mg, you'll give one injection. If your prescribed dose is 300 mg, you'll need to use two Cosentyx Sensoready pens to give two injections. You should choose a different injection site for each injection if your dose requires two injections. Wash your hands, then clean the injection site with an alcohol wipe and allow it to dry. You may inject Cosentyx Sensoready doses into the front of your thighs, your lower stomach, or your upper outer arms (if someone else is giving your injection). Avoid giving an injection into skin that is tender, bruised, red or discolored, hard, or scaly. Do not inject into an area of skin affected by psoriasis, or area with stretch marks or scars. Do not shake the Sensoready pen. shake the Sensoready pen. Remove and throw away the cap. Hold the Sensoready pen at a 90-degree angle against the injection site. Press and hold the Sensoready pen firmly against the skin at the injection site. You should hear the first 'click' sound, which signals the injection has started. Continue holding the Sensoready pen firmly against your skin. Watch the progress of the injection using the 360-degree viewing window on the Sensoready pen. You should see a green moving indicator. When the pen sounds a second 'click', the injection is nearly complete. Continue holding the Sensoready pen against your skin until the green moving indicator fills the viewing window and stops moving. Once the green indicator stops moving, the injection is complete. You may now dispose of the Sensoready pen into a sharps container. If your dose is 300 mg, repeat these steps with a new Sensoready pen at a different injection site. If you're prescribed Cosentyx UnoReady or Sensoready, you may wonder how effective either drug is for treating your condition. Prescribing information: Here's a brief look at how effective Cosentyx UnoReady and Sensoready were found to be in clinical trials. Clinical trials found Cosentyx UnoReady and Sensoeady effective at treating: For details about how these drugs performed in clinical trials, see the prescribing information for Cosentyx UnoReady and Sensoready. Keep in mind that trial results may not apply to your individual health situation. Treatment guidelines: Another way to see whether a drug is considered effective is to look at treatment guidelines. When an organization includes certain drugs in treatment guidelines, this means that research has shown the drug to be safe and effective. Cosentyx UnoReady and Sensoready both contain the same active ingredient (what makes a drug work), secukinumab. Below is information on treatment guidelines that recommend secukinumab as a treatment for approved uses of Cosentyx UnoReady and Sensoready: Cosentyx UnoReady and Sensoready may not be right for you if you have certain medical conditions or other factors that affect your health. The two drugs share some of the same precautions, but they also have different ones. Some of these precautions are mentioned below. If any of the following medical conditions or other health factors are relevant to you, talk with your doctor before using Cosentyx UnoReady or Sensoready. The Cosentyx UnoReady and Sensoready pens are approved to treat the same conditions, but differences between the two can determine which is a better fit for you. A few key differences include: The UnoReady pen cap isn't made with latex, making it a better option if you have a latex allergy. The UnoReady pen can only deliver a 300-mg dose. The Sensoready pen, on the other hand, delivers a 150-mg dose. Two Sensoready pens may be used to give a 300-mg dose. This makes the Sensoready pen more versatile in its dosing options. The UnoReady pen is rectangular in shape, while the Sensoready pen is triangular. You may find one pen more comfortable to hold and use than the other based on your preferences. To learn more about how the Cosentyx UnoReady and Sensoready pens compare, talk with your doctor or pharmacist. They can help decide if either pen is a better option for you. Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses. Psoriasis Psoriatic Arthritis Pharmacy / Pharmacist Drugs Arthritis
Medscape
22-05-2025
- Health
- Medscape
Secukinumab Cuts Chronic Pain in Hidradenitis Suppurativa
Compared with placebo, secukinumab demonstrated superior pain reduction in moderate to severe hidradenitis suppurativa in two phase 3 trials. Improvements in pain were sustained through week 52 and were associated with better quality of life outcomes. METHODOLOGY: Researchers analysed 1084 patients with moderate to severe hidradenitis suppurativa from two phase 3 trials (SUNSHINE and SUNRISE) and randomly assigned them to receive secukinumab 300 mg subcutaneously every 2 weeks (SECQ2W) or every 4 weeks (SECQ4W) or placebo until week 16. At week 16, patients randomly assigned to receive placebo switched to receive SECQ2W (placebo-SECQ2W) or SECQ4W (placebo-SECQ4W) until week 52, whereas those originally randomly assigned to receive SECQ2W or SECQ4W continued this treatment until week 52. Pain was assessed using the Patient's Global Assessment of Skin Pain on a continuous numeric rating scale (NRS) through week 52; the severity of pain was categorised into quartiles on the basis of baseline scores (NRS ≤ 3.3, NRS > 3.3 to ≤ 5.4, NRS > 5.4 to ≤ 7.2, and NRS > 7.2). This post hoc analysis of pooled data from the two trials evaluated the effect of secukinumab on multiple aspects of pain and in different subgroups of patients with hidradenitis suppurativa. TAKEAWAY: At week 16, a greater mean absolute change from baseline in skin pain was observed with secukinumab treatment (SECQ2W: mean difference, −1.35; SECQ4W: mean difference, −1.05) than with placebo (mean difference, −0.47). Reductions in skin pain in the secukinumab groups at week 16 were sustained, with a trend for improvement through week 52. Similar improvements were observed in placebo-SECQ2W and placebo-SECQ4W groups. Among patients with severe baseline pain (NRS > 7.2), 20.0% in the SECQ2W group and 12.7% in the SECQ4W group achieved significant pain reduction (NRS ≤ 3.3) at week 16. Patients achieving lower pain scores (NRS ≤ 3.3) experienced better quality of life outcomes. In the secukinumab groups, the proportion of patients requiring pain medication decreased at weeks 16 and 52 compared with baseline. IN PRACTICE: "This post hoc analysis of the SUNSHINE and SUNRISE phase 3 trials highlights the benefits of secukinumab in reducing skin pain in patients with moderate to severe HS [hidradenitis suppurativa], seen within a few weeks of treatment initiation, and sustained, with a trend for improvement, through week 52," the authors wrote. "Importantly, improvements in disease-related pain were associated with improvements in QoL [quality of life] of patients, as well as a decrease in the proportion of patients taking pain medication," they added. SOURCE: This study was led by John R. Ingram, Department of Dermatology & Academic Wound Healing, Division of Infection and Immunity, Cardiff University, Cardiff, Wales. It was published online on May 15, 2025, in Dermatology and Therapy . LIMITATIONS: Changes in skin pain observed may have been influenced by the use of concomitant medications and cannot be fully attributed to the study treatment alone. The cutoffs used for assessing skin pain categories were based on baseline NRS quartiles due to the absence of validated cutoffs for the hidradenitis suppurativa population. Additionally, the study population predominantly consisted of self-reported White participants, with a relatively low proportion of Black patients potentially limiting the generalisability of the findings to the broader global population. DISCLOSURES: This study was funded by Novartis Pharma AG, Basel, Switzerland. One author declared being an employee and stockholder at Novartis Ireland Limited, Dublin, Ireland. Four authors declared being employees of Novartis Pharma AG, Basel, Switzerland. One author declared being an employee of Novartis Pharmaceuticals, East Hanover, New Jersey, United States, at the time of the study. Several authors reported receiving consulting fees and having other ties with various sources.
